Get the Stockscreener App
194.82
6.98%
12.71
Pre-market:
195.82
1.00
+0.51%
Moderna Inc stock is traded at $194.82, with a volume of 16.53M.
It is up +6.98% in the last 24 hours and up +40.27% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$182.11
Open:
$180.6
24h Volume:
16.53M
Relative Volume:
1.03
Market Cap:
$77.78B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-23.92
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+23.25%
1M Performance:
+40.27%
6M Performance:
+279.47%
1Y Performance:
+652.78%
1-Day Range:
$180.39
$195.71
1-Week Range:
$150.26
$195.71
52-Week Range:
$22.28
$195.71
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna CEO’s Realistic Approach to Innovation - WSJ
Moderna, Inc. Stock Analysis: Momentum Builds Amid Overbought Signals - The Cryptonomist
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Moderna stock heads into the open after a 6.98 percent gain - AD HOC NEWS
Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24. - finance.yahoo.com
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better - Stocktwits
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
$Moderna (MRNA.US)$ thanks - Moomoo
Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak - finance.yahoo.com
From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done - finance.yahoo.com
Moderna Rises as Cancer-Vaccine Momentum and Pipeline Visibility Stay in Focus - quiverquant.com
Moderna Inc Stock (MRNA) Moved Up by 5.91% on Sep 24: What Investors Need To Know - TradingKey
Moderna's View of the Global Pharma Industry - WSJ
Top Biotech Stocks To Keep An Eye OnSeptember 24th - MarketBeat
A New Cancer Vaccine Shows Promise for Melanoma—Here’s What Doctors Know So Far - elle.com
Moderna stock trades below its 52-week high before cancer data - AD HOC NEWS
Dear Doctor: Should I hold off on my flu shot until I'm eligible for the new version? - syracuse.com
Biotech Stocks At 52-Week HighsTKNO, MRNA, ATRC, ILMN - RTTNews
Nykredit A S Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
Engineers Gate Manager LP Cuts Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna stock gains 4.5 percent ahead of the open - ad-hoc-news.de
Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines - Barron's
Moderna stock rises 5.6 percent at the close - AD HOC NEWS
Healthcare Stocks Fall -- Healthcare Roundup - marketscreener.com
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID - finance.yahoo.com
symbol__ Stock Quote Price and Forecast - CNN
MRNA: Broad mRNA platform advances, led by oncology and rare disease innovation, drive future growth - TradingView
Moderna Stock Forecast: MRNA Hits $187 as Melanoma Vaccine Fuels Rally - FXLeaders
Moderna’s mRNA flu shot hits the target - Science News
Moderna stock rises 5.6 percent on melanoma data - AD HOC NEWS
Moderna stock gains 5.6 percent ahead of the open - AD HOC NEWS
Moderna stock gains 5.6 percent as melanoma data approaches - AD HOC NEWS
Moderna (MRNA) Co Founder Joined An AI Drug Discovery Company - simplywall.st
Moderna (NASDAQ:MRNA) Trading Up 5.6%What's Next? - MarketBeat
Moderna, Inc.'s stock price soars to $182.56, marking a robust 5.56% increase: A lucrative investment opportunity - Smartkarma
Moderna stock gains 5.16 percent after the close - AD HOC NEWS
Moderna's Surge Faces Wall Street Skepticism as Analysts Question Cancer Vaccine Rally - finance.biggo.com
Was Moderna Stock's Cancer Vaccine Run Visible In Advance? - finance.yahoo.com
Was Moderna Stock’s Cancer Vaccine Run Visible In Advance? - trefis.com
Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis - TradingKey
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No." - The Globe and Mail
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up? - finance.yahoo.com
UBS reiterates Moderna stock rating ahead of melanoma data - Investing.com
How the Merck-Moderna mRNA melanoma vaccine is built per patient - qz.com
Top 3 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going - finance.yahoo.com
Moderna Says Sanofi Wants To 'Unjustly Profit' In Vax IP Suit - law360.com
Moderna (MRNA) Stock Trades Up, Here Is Why - Yahoo Finance
Stocks in Demand: MRNA and SAMAIDEN Lead Investor Attentions - Moomoo
Moderna, Inc.’s stock price skyrockets to $172.94, marking an impressive 12.27% surge - Smartkarma
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
1.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):